Actively Recruiting
Exercise Training for the Improvement of Immune Activity and Treatment Outcomes During Immunotherapy for Non-small Cell Lung Cancer, BOOST Trial
Led by Fred Hutchinson Cancer Center · Updated on 2026-02-06
100
Participants Needed
1
Research Sites
122 weeks
Total Duration
On this page
Sponsors
F
Fred Hutchinson Cancer Center
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This clinical trial studies how well exercise training works in improving immune activity and treatment tolerance and response in patients with non-small cell lung cancer (NSCLC) who are receiving immunotherapy. Immunotherapy may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. The use of immunotherapy for the treatment of NSCLC has been rapidly increasing. Although immunotherapy have shown great potential in cancer therapy, not all patients benefit from this therapy and resistance to it can occur. This could be due to poor immune activity. It has been shown that exercise can enhance systemic immune activity in various ways. The exercise training used in this study is aerobic interval training. Aerobic interval training increases the heart rate and the body's use of oxygen and alternates short periods of intense aerobic exercise with less intense recovery periods. This may cause biological changes which may improve immune activity and treatment response in patients with NSCLC who are receiving immunotherapy.
CONDITIONS
Official Title
Exercise Training for the Improvement of Immune Activity and Treatment Outcomes During Immunotherapy for Non-small Cell Lung Cancer, BOOST Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age �38 18 years.
- Histologically diagnosed with NSCLC.
- Currently receiving immunotherapy with at least one month of treatment completed.
- Planning to continue immunotherapy for at least 24 weeks at recruitment.
- ECOG Performance Status of 0-2.
- Able to understand and willing to provide study consent.
You will not qualify if you...
- Participating in 150 minutes or more of moderate-to-vigorous aerobic exercise per week over the past month.
- Having medically unstable or uncontrolled conditions deemed high-risk for exercise, including recent myocardial infarction, uncontrolled arrhythmias, decompensated heart failure, unstable angina, severe aortic stenosis, uncontrolled hypertension (�38 180/110 mmHg), uncontrolled diabetes (HbA1c > 10% with symptoms), severe COPD requiring recent hospitalization, or bone metastases with fracture risk.
- At high risk for noncompliance with study procedures based on missed appointments, poor communication, or difficulty following instructions.
- Non-English speaking preventing participation in surveys.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States, 98109
Actively Recruiting
Research Team
D
Dong-Woo Kang, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here